ACTRN12617001061325招募中2 期
A Phase IIa, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with Pembrolizumab in Subjects with Chemotherapy Naïve, PD-L1 high metastatic Non–Small Cell Lung Cancer (NSCLC)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Agenus Inc.
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 —（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDS4501A in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination with Rituximab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's LymphomaChronic Lymphocityc LeukemiaNon-Hodgkin Lymphoma10024324NL-OMON39626Genentech Inc.15
已完成
1 期
A drug-drug interaction trial between AR882, fluconazole, carbamazepine, celecoxib, and sulfasalazine in healthy particpantsGoutInflammatory and Immune System - Other inflammatory or immune system disordersMusculoskeletal - Other muscular and skeletal disordersACTRN12623001038684Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc54
尚未招募
不适用
QPiAML 2020 studyNL-OMON19921Prinses Máxima Centrum voor Kinderoncologie60
招募中
1 期
CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML with normal NPM1.newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AMLCTIS2023-505000-27-01Prinses Maxima Centrum voor Kinderoncologie B.V.41
招募中
不适用
A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with spinocerebellar ataxia types 1, 3 and Huntington*s diseaseSpinocerebellar ataxiaa group of rare, inherited, genetic disorders that affect specific parts of the brain, including the cerebellum (the center of motor coordination), brain stem and spinal cord. These disorders can cause problems such as problems with balance, coordination, walking, swallowing and speaking.Huntingtons Disease10029299NL-OMON53759VICO Therapeutics B.V.20